These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 7139066)
21. Biological behavior and metabolic fate of the BAL analogues DMSA and DMPS. McGown EL; Tillotson JA; Knudsen JJ; Dumlao CR Proc West Pharmacol Soc; 1984; 27():169-76. PubMed ID: 6093126 [No Abstract] [Full Text] [Related]
22. Complexing activity and excretion of 2,3-dimercapto-1-propane sulfonate in rat kidney. Klotzbach JM; Diamond GL Am J Physiol; 1988 Jun; 254(6 Pt 2):F871-8. PubMed ID: 3381889 [TBL] [Abstract][Full Text] [Related]
23. Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs. Supko JG; Garcia-Carbonero R; Puchalski TA; Malspeis L Cancer Chemother Pharmacol; 2001 Sep; 48(3):202-8. PubMed ID: 11592341 [TBL] [Abstract][Full Text] [Related]
24. Modipafant, a new PAF antagonist: pharmacokinetics and disposition in rat, dog and man. Jezequel SG; Uden S; Wastall P Xenobiotica; 1996 Sep; 26(9):963-75. PubMed ID: 8893043 [TBL] [Abstract][Full Text] [Related]
25. Acute effects of the heavy metal antidotes DMPS and DMSA on circulation, respiration, and blood homoeostasis in dogs. Klimmek R; Krettek C; Werner HW Arch Toxicol; 1993; 67(6):428-34. PubMed ID: 8215913 [TBL] [Abstract][Full Text] [Related]
26. Bioavailability and disposition kinetics of HI-6 in Beagle dogs. Baggot JD; Buckpitt A; Johnson D; Brennan P; Chung H Biopharm Drug Dispos; 1993 Mar; 14(2):93-105. PubMed ID: 8453028 [TBL] [Abstract][Full Text] [Related]
27. Effects of repeated treatment with sodium 2,3-dimercaptopropane-1-sulfonate in beagle dogs. Szinicz L; Wiedemann P; Häring H; Weger N Arzneimittelforschung; 1983; 33(6):818-21. PubMed ID: 6684434 [No Abstract] [Full Text] [Related]
28. Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man. Ahr HJ; Boberg M; Brendel E; Krause HP; Steinke W Arzneimittelforschung; 1997 Jun; 47(6):734-45. PubMed ID: 9239452 [TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of 4-acetylaminophenylacetic acid. 1st communication: absorption, distribution, metabolism and excretion in mice, rats, dogs and monkeys after single administration of 14C-labeled compound. Sugihara K; Morino A; Nomura A; Iida S; Sugiyama M Arzneimittelforschung; 1990 Jul; 40(7):800-5. PubMed ID: 2222556 [TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of glucosamine in the dog and in man. Setnikar I; Giacchetti C; Zanolo G Arzneimittelforschung; 1986 Apr; 36(4):729-35. PubMed ID: 3718596 [TBL] [Abstract][Full Text] [Related]
31. Metabolic fate of the new angiotensin-converting enzyme inhibitor imidapril in animals. 1st communication: absorption, pharmacokinetics and excretion in rats and dogs. Yamada Y; Endo M; Kohno M; Otsuka M; Takaiti O Arzneimittelforschung; 1992 Apr; 42(4):457-65. PubMed ID: 1642668 [TBL] [Abstract][Full Text] [Related]
32. Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. Setnikar I; Rovati LC Arzneimittelforschung; 2001 Sep; 51(9):699-725. PubMed ID: 11642003 [TBL] [Abstract][Full Text] [Related]
33. Optical isomers of 2,3-dimercapto-1-propanesulfonate: antidotal activity, in vitro and in vivo, against sodium arsenite. Hsu CA; Aposhian HV; Heydolph S; Parr W J Pharmacol Exp Ther; 1983 Feb; 224(2):314-8. PubMed ID: 6687396 [TBL] [Abstract][Full Text] [Related]
34. Distribution and excretion of the mercury chelating agent sodium 2,3-dimercaptopropane-1-sulfonate in the rat. Gabard B Arch Toxicol; 1978 Feb; 39(4):289-98. PubMed ID: 580372 [TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of triclopyr (3,5,6-trichloro-2-pyridinyloxyacetic acid) in the beagle dog and rhesus monkey: perspective on the reduced capacity of dogs to excrete this organic acid relative to the rat, monkey, and human. Timchalk C; Nolan RJ Toxicol Appl Pharmacol; 1997 Jun; 144(2):268-78. PubMed ID: 9194410 [TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys. Nonaka K; Tsujioka T; Tougou K; Mukai H Arzneimittelforschung; 2003; 53(9):612-20. PubMed ID: 14558434 [TBL] [Abstract][Full Text] [Related]
37. Comparative pharmacokinetics of [14C]metosulam (N-[2,6-dichloro-3-methylphenyl]-5,7-dimethoxy-1,2,4- triazolo[1,5a]-pyrimidine-2-sulfonamide) in rats, mice and dogs. Timchalk C; Dryzga MD; Johnson KA; Eddy SL; Freshour NL; Kropscott BE; Nolan RJ J Appl Toxicol; 1997; 17(1):9-21. PubMed ID: 9048223 [TBL] [Abstract][Full Text] [Related]
38. Bioavailability of 14C-sulpiride in dogs. Alam AS; Imondi AR; Udinsky J; Hagerman LM Arch Int Pharmacodyn Ther; 1979 Nov; 242(1):4-13. PubMed ID: 543747 [TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of nimodipine. I. Communication: absorption, concentration in plasma and excretion after single administration of [14C]nimodipine in rat, dog and monkey. Maruhn D; Siefert HM; Weber H; Rämsch K; Suwelack D Arzneimittelforschung; 1985; 35(12):1781-6. PubMed ID: 4096729 [TBL] [Abstract][Full Text] [Related]